Navigation Links
XTENT Announces First Quarter 2008 Financial Results
Date:4/28/2008

Six-month CUSTOM III long and multi-lesion clinical trial data to be

presented as late-breaking data at EuroPCR on Tuesday, May 13

MENLO PARK, Calif., April 28 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the first quarter ended March 31, 2008.

The company reported a net loss of $12.5 million, or $0.54 per share, for the first quarter of 2008, compared to a net loss of $7.9 million, or $0.55 per share, for the first quarter of 2007. The company's net loss for the first quarter of 2008 was based on weighted average shares outstanding of 22.9 million as compared to 14.5 million weighted average shares outstanding for the first quarter of 2007. At March 31, 2008, XTENT had cash, cash equivalents and short-term investments of $46.5 million.

Research and development expenses increased to $9.4 million in the first quarter of 2008 from $6.2 million for the same period in 2007, primarily due to an increased number of research and development personnel, expenditures for prototype parts and supplies as well as costs incurred for clinical trials. General and administrative expenses were $3.4 million in the first quarter of 2008 versus $2.5 million for the same period in 2007, primarily due to an increase in personnel and other related costs.

"We continue to make progress toward bringing the next generation in drug-eluting stent technology to physicians and their patients with coronary artery disease," said Gregory D. Casciaro, XTENT's President and CEO. "We are privileged to report that our CUSTOM III trial results have been selected for presentation during the Late-Breaking Trials session at the premiere international interventional cardiology meeting (EuroPCR) held next month in Barcelona, Spain."

CUSTOM III Long and Multi-lesion Trial Six-Month Data To Be Presented At EuroPCR

Six-month follow-up data from the CUSTOM III clinical trial will be presented at the annual EuroPCR meeting, taking place May 13 through 16 in Barcelona, Spain. The company will exhibit as well as host a symposium on customizable drug-eluting stents.

Schedule of XTENT Events for EuroPCR

Tuesday, May 13, 2008, 3:30-6:30 p.m. CEST

Late-Breaking Clinical Trial: CUSTOM III trial 6-month follow-up results. Bernard de Bruyne, M.D., Ph.D., Cardiovascular Center, OLV Hospital in Aalst, Belgium, the principal investigator of the CUSTOM III clinical trial, will present six-month follow-up data from the CUSTOM III trial evaluating use of the Custom NX(R) Drug Eluting Stent (DES) System in patients with long or multiple coronary lesions.

Wednesday, May 14, 2008, 5:00-6:30 p.m. CEST

Evening symposium: Customizable drug-eluting stents: a breakthrough approach to the percutaneous treatment of coronary artery disease.

The symposium will provide an overview of the Custom NX DES System with respect to the treatment of long and multi-lesion coronary artery disease, and the CUSTOM clinical program.

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6mm segment and allows for the placement of up to 60mm of stent.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of its regulatory filings, the timing of the commercialization of its products and the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

XTENT, INC.

(a development stage company)

Condensed Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended

March 31,

2008 2007

Operating expenses:

Research and development (1) $9,421 $6,223

General and administrative (1) 3,442 2,461

Total operating expenses 12,863 8,684

Loss from operations (12,863) (8,684)

Interest and other income, net 406 749

Net loss $(12,457) $(7,935)

Net loss per share - basic and diluted $(0.54) $(0.55)

Weighted-average common shares outstanding

used in per share calculation 22,923 14,482

(1) Includes the following stock-based

compensation charges:

Research and development $388 $388

General and administrative $650 $420

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

March 31, 2008 December 31, 2007

Cash, cash equivalents and short term

investments $46,494 $57,760

Working capital 43,331 54,581

Total assets 51,649 62,415

Deficit accumulated during the development

stage (105,317) (92,860)

Total stockholders' equity 47,062 58,331


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 4, 2016 Summary Breast cancer, a ... the most common cancer in women worldwide, accounting for ... prevalent. The number of women diagnosed with breast cancer ... number of deaths has declined due to earlier diagnosis ... been revolutionized in the past four decades, especially with ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and ... launch of a new DRTV campaign with Belly Bands. , Having a dog is ... sprays to puppy pads and find nothing works, get Belly Bands, the easiest ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention efforts, ... scientific initiatives have all marked the last 12 months at Roswell Park Cancer ... the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments ...
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
Breaking Medicine News(10 mins):